Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An Unexpected Response to Imatinib in a "Wild-Type" Gastrointestinal Stromal Tumor.

Oncology research and treatment - 1 Jan 2020

Gheysen Mathilde, Vander Borght Sara, Lehnert Stefan, Vanslembrouck Ragna, Vanden Bempt Isabelle, Schöffski Patrick

Abstract excerpt

INTRODUCTION: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract and the most frequent sarcomas in some geographic regions. In patients with metastatic GIST, the tyrosine kinase inhibitor imatinib is the first-line standard of care. Mutations in KIT or specific platelet-derived growth factor receptor alpha (PDGFRA) gene aberrations in the tumor cells...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Gastrointestinal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastrointestinal Stromal Tumors

Share to High-Throughput Nucleotide Sequencing

Share to Imatinib Mesylate

Share to Molecular Targeted Therapy

Share to Protein Kinase Inhibitors

Share to Treatment Outcome

Source

Identifiers

PMID: 32640452
DOI: 10.1159/000508536

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An Unexpected Response to Imatinib in a "Wild-Type" Gastrointestinal Stromal Tumor.PMID 32640452Read ↗

Emerging Targeted Therapeutic Strategies to Overcome Imatinib Resistance of Gastrointestinal Stromal Tumors.Semantic proximity Read ↗

Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors.Semantic proximity Read ↗

Utility of Clinical Next Generation Sequencing Tests in KIT/PDGFRA/SDH Wild-Type Gastrointestinal Stromal TumorsSemantic proximity Read ↗

Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFRα genotype evaluated by next generation sequencing (NGS).Semantic proximity Read ↗

Targeted therapy and personalized medicine in gastrointestinal stromal tumors: drug resistance, mechanisms, and treatment strategiesSemantic proximity Read ↗

Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA AnalysisSemantic proximity Read ↗

Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.Semantic proximity Read ↗

Gastrointestinal stromal tumors: overview of pathologic features, molecular biology, and therapy with imatinib mesylate.Semantic proximity Read ↗

Targeted therapies in gastrointestinal stromal tumors.Semantic proximity Read ↗

Multiomic Landscape of Gastrointestinal Stromal Tumors in a Real-World Patient Cohort of 1,427 Cases.Semantic proximity Read ↗

Comprehensive targeted next‐generation sequencing approach in the molecular diagnosis of gastrointestinal stromal tumorSemantic proximity Read ↗

Gastrointestinal Stromal Tumors: Molecular Mechanisms of Drug Resistance and Advances in Therapeutic Strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.